On the other hand, CCL2 could be a good candidate as a biomarker to follow-up the conversion of mild AD patients to moderate AD patients, and our BBB model could be a useful tool to detect the decrease of CCL2 over the progression of AD. Here, CCL2 is linked to Alzheimer disease.